LAM Pilot Study With Imatinib Mesylate
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Everolimus; Sirolimus
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- Acronyms LAMP-1
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2019 Planned End Date changed from 31 Jan 2019 to 29 Jun 2019.